Recurrent Disease Clinical Trial
Official title:
A Phase II Study Of Su011248 In Patients With Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma.
Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So at the light of these pre-clinical and clinical data, it seems interesting and promising to test SU011248 in these poor prognosis patients.
This is an open-label phase II, multicenter study. Eligible patients will receive SU011248 in
monotherapy (37.5 mg given continuously without interruption). Tumor check-up will be
performed every 6-8 weeks. Treatment will be continued until disease progression or
unacceptable toxicities according to the patient or the investigator (the median for
treatment in renal cell study was 8 months).
Since, head and neck tumors are easily accessible for iterative biopsy, this study will offer
the opportunity to get tumor biopsies before and after SU011248. Our study will allow
translational research with biopsies at crucial timing: at baseline before any treatment, ,
during the treatment with SU011248 (cycle 1, between week 4 and 6), for patients with stable
disease or partial response, a new biopsy will be performed at the time of disease
progression to try to understand the mechanisms of tumor or resistance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02204761 -
Proton Beam Re-Irradiation in Thoracic Cancers
|
N/A | |
Completed |
NCT01445080 -
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT03525392 -
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
|
Phase 1 | |
Completed |
NCT01794845 -
Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
|
Phase 2 | |
Completed |
NCT02210858 -
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT05432518 -
Pilot Trial for Treatment of Recurrent Glioblastoma
|
Early Phase 1 | |
Completed |
NCT00351975 -
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
|
Phase 1 | |
Completed |
NCT03060096 -
Stepped-Care Telehealth for Distress in Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT03591666 -
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
|
Phase 2 | |
Completed |
NCT00036738 -
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
|
Phase 2 | |
Recruiting |
NCT05260671 -
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
|
Phase 2 | |
Completed |
NCT01737450 -
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
|
Phase 2 | |
Completed |
NCT03415477 -
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088719 -
Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence
|
||
Terminated |
NCT02488512 -
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
|
Phase 2 | |
Recruiting |
NCT02747732 -
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
|
Phase 2 | |
Completed |
NCT00383474 -
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
|
Phase 1 | |
Completed |
NCT00003145 -
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT06014619 -
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
|
||
Active, not recruiting |
NCT03792256 -
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
|
Phase 1 |